Elevated UHRF1 predicts unfavorable clinical outcomes in adult T-cell leukemia/lymphoma: Clinicopathological analysis and preliminary in vitro observations
- 1Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
- 2Department of Hematology, Ningde Municipal Hospital, Ningde, China.
- 3Department of Traditional Chinese Medicine, Ningde Municipal Hospital, Ningde, China.
Abstract
Background: UHRF1 has been established as a susceptibility gene in multiple cancer types; however, its functional role in the pathogenesis of adult T-cell leukemia/lymphoma (ATLL) remains poorly defined. This study aimed to investigate UHRF1 expression in ATLL and assess its clinical and biological significance. Methods: Immunohistochemistry was performed to evaluate UHRF1 protein expression in tumor tissues from 72 ATLL patients and 30 reactive lymphadenopathy controls. Univariate Cox’s proportional hazard regression model was used to screen the factors affecting OS and PFS, and multivariate Cox’s proportional hazard regression model was used to screen independent prognostic factors in ATLL. UHRF1 expression in the HuT-102 ATLL cell line and MT-4 cell line was evaluated by Western blotting and quantitative PCR, and shRNA-mediated knockdown was used to assess proliferation and apoptosis. Results: UHRF1 protein was highly expressed in primary ATLL samples (P < 0.001, median 26.562 vs. 1.306), and the percentage of positive pixels (%Area) significantly higher than that in the control group (P < 0.001, median 9.914 vs. 0.574). Multivariate Cox regression analysis demonstrated that UHRF1 expression remained an independent prognostic predictor after adjustment for clinicopathological characteristics. For overall survival (OS): P = 0.026, HR = 2.397, 95%CI: 1.108–5.184; for progression-free survival (PFS): P = 0.042, HR = 1.959, 95%CI: 1.025–3.744. Mechanistically, UHRF1 knockdown significantly suppressed proliferation and induced apoptosis in ATLL cell lines (HuT-102 cells and MT-4 cell). Co-immunoprecipitation detected no stable interaction between UHRF1 and either AMPK or the PP2A catalytic subunit PPP2CA, and UHRF1 knockdown did not significantly alter LKB1, PPP2R4, or the p-AMPK (Thr172)/AMPK ratio; whether UHRF1 intersects with AMPK signaling remains to be determined. These findings identify UHRF1 as an independent adverse prognostic indicator in ATLL and provide preliminary biological evidence, though the underlying mechanisms require further validation in larger cohorts and in vivo models.
Related
- Dynamic changes in clinicopathological variables and gene expression in dogs with immune-mediated hemolytic anemia
- Study on the association between the low-density lipoprotein to high-density lipoprotein ratio and clinicopathological characteristics of breast cancer: A retrospective analysis incorporating subgroup evaluations by age, body mass index, and menopausal status
- Genotype-dependent growth and essential oil responses of Salvia officinalis under combined elevated CO2 and heat stress
- Microclimate Comfort of Elevated Bridge Underpass Spaces Based on Sound and Thermal Environments: A Case Study of Fuzhou and Xiamen, Fujian Province
- Examining urban weed response to elevated salt levels
BibTeX
@article{lin2026elevated,
title = {{Elevated UHRF1 predicts unfavorable clinical outcomes in adult T-cell leukemia/lymphoma: Clinicopathological analysis and preliminary in vitro observations}},
author = {Ying Lin and Rong-Dong Zhang and Xin-Yu Xu and Huang-Zhou Jiang and Ren-Li Chen and Jian-Zhen Shen},
journal = {PLOS One},
year = {2026},
month = nov,
doi = {10.1371/journal.pone.0362674},
url = {https://doi.org/10.1371/journal.pone.0362674},
note = {CC BY},
}
RIS
TY - JOUR
TI - Elevated UHRF1 predicts unfavorable clinical outcomes in adult T-cell leukemia/lymphoma: Clinicopathological analysis and preliminary in vitro observations
AU - Ying Lin
AU - Rong-Dong Zhang
AU - Xin-Yu Xu
AU - Huang-Zhou Jiang
AU - Ren-Li Chen
AU - Jian-Zhen Shen
PY - 2026
DA - 2026/11/11
JO - PLOS One
DO - 10.1371/journal.pone.0362674
UR - https://doi.org/10.1371/journal.pone.0362674
AB - Background: UHRF1 has been established as a susceptibility gene in multiple cancer types; however, its functional role in the pathogenesis of adult T-cell leukemia/lymphoma (ATLL) remains poorly defined. This study aimed to investigate UHRF1 expression in ATLL and assess its clinical and biological significance. Methods: Immunohistochemistry was performed to evaluate UHRF1 protein expression in tumor tissues from 72 ATLL patients and 30 reactive lymphadenopathy controls. Univariate Cox’s proportional hazard regression model was used to screen the factors affecting OS and PFS, and multivariate Cox’s proportional hazard regression model was used to screen independent prognostic factors in ATLL. UHRF1 expression in the HuT-102 ATLL cell line and MT-4 cell line was evaluated by Western blotting and quantitative PCR, and shRNA-mediated knockdown was used to assess proliferation and apoptosis. Results: UHRF1 protein was highly expressed in primary ATLL samples (P < 0.001, median 26.562 vs. 1.306), and the percentage of positive pixels (%Area) significantly higher than that in the control group (P < 0.001, median 9.914 vs. 0.574). Multivariate Cox regression analysis demonstrated that UHRF1 expression remained an independent prognostic predictor after adjustment for clinicopathological characteristics. For overall survival (OS): P = 0.026, HR = 2.397, 95%CI: 1.108–5.184; for progression-free survival (PFS): P = 0.042, HR = 1.959, 95%CI: 1.025–3.744. Mechanistically, UHRF1 knockdown significantly suppressed proliferation and induced apoptosis in ATLL cell lines (HuT-102 cells and MT-4 cell). Co-immunoprecipitation detected no stable interaction between UHRF1 and either AMPK or the PP2A catalytic subunit PPP2CA, and UHRF1 knockdown did not significantly alter LKB1, PPP2R4, or the p-AMPK (Thr172)/AMPK ratio; whether UHRF1 intersects with AMPK signaling remains to be determined. These findings identify UHRF1 as an independent adverse prognostic indicator in ATLL and provide preliminary biological evidence, though the underlying mechanisms require further validation in larger cohorts and in vivo models.
SN - 1932-6203
ER -